financetom
Business
financetom
/
Business
/
IHS Closes Sale of Rwanda Business to Paradigm Tower Ventures
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IHS Closes Sale of Rwanda Business to Paradigm Tower Ventures
Oct 9, 2025 8:58 AM

11:15 AM EDT, 10/09/2025 (MT Newswires) -- IHS (IHS) said Thursday that it has completed the sale of its Rwanda business, including about 1,467 sites, to Paradigm Tower Ventures.

The company said previously that the sale reflects an enterprise value of $274.5 million for IHS Rwanda.

Price: 6.81, Change: -0.06, Percent Change: -0.80

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brevan Howard to invest $200 million in Catalio healthcare fund, say sources
Brevan Howard to invest $200 million in Catalio healthcare fund, say sources
Nov 7, 2025
* Brevan makes $200 mln commitment to Catalio Public Equities fund * Move highlights trend of hedge funds making external investments * Catalio fund posted 49% return net of fees since began in 2023 By Nell Mackenzie LONDON, Nov 7 (Reuters) - Brevan Howard has made a $200 million commitment to Catalio Capital Management's healthcare stock fund, two sources close...
Constellation Energy misses quarterly profit estimates, narrows 2025 forecast
Constellation Energy misses quarterly profit estimates, narrows 2025 forecast
Nov 7, 2025
Nov 7 (Reuters) - U.S. utility Constellation Energy ( CEG ) on Friday narrowed the upper end of its full-year forecast, after missing third-quarter estimates on higher operating expenses. Shares of the Baltimore, Maryland-based company fell 4% in premarket trading following the results. Higher operating expenses, driven by infrastructure investments and maintenance, tend to squeeze margins for utilities such as...
Rhythm Pharmaceuticals Says FDA Extends Review of Imcivree Application to March 2026
Rhythm Pharmaceuticals Says FDA Extends Review of Imcivree Application to March 2026
Nov 7, 2025
08:02 AM EST, 11/07/2025 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Friday the US Food and Drug Administration extended the review period for its supplemental new drug application for Imcivree, or setmelanotide, for treating acquired hypothalamic obesity by three months to March 20, 2026, from December 20, 2025. The company said the extension follows an October request from...
Koppers Q3 sales down 12.4%, miss estimates
Koppers Q3 sales down 12.4%, miss estimates
Nov 7, 2025
Overview * Koppers ( KOP ) Q3 sales fell 12.4% yr/yr, missing analyst expectations * Adjusted EPS for Q3 missed analyst expectations * Company completed sale of Railroad Structures business to simplify portfolio Outlook * Koppers ( KOP ) revises 2025 sales forecast to approximately $1.9 bln * Company tightens 2025 adjusted EBITDA forecast to $255 mln-$260 mln * Koppers...
Copyright 2023-2026 - www.financetom.com All Rights Reserved